Growth hormone deficiency
Drug research and approvals for growth hormone deficiency: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 20 studies of growth hormone deficiency are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, FDA has 8 approved and 8 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 20
- Trials authorized in Canada: 12
- FDA orphan approvals: 8
- EU medicines: 3
Recruiting Now
Newest start dates first, of 20 recruiting on ClinicalTrials.gov ↗- Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone DeficiencyNCT07551804 · Phase 2 · Xiamen Amoytop Biotech Co., Ltd. · starts Jun 10, 2026
- GB06 Phase III Trial for Pediatric Growth Hormone DeficiencyNCT07553351 · Phase 3 · Kexing Biopharm Co., Ltd. · starts Jun 6, 2026
- Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyNCT06948214 · Phase 3 · Lumos Pharma · starts May 20, 2026
- A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)NCT07264595 · Phase 1 / Phase 2 · Changchun GeneScience Pharmaceutical Co., Ltd. · starts Jan 18, 2026
- Assessment of Body Composition in Children Treated With Growth Hormone for the Indication of Isolated Non-acquired…NCT07333521 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Jan 13, 2026
- Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and…NCT07221851 · Phase 3 · Ascendis Pharma A/S · starts Dec 12, 2025
- REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)NCT07412782 · Not applicable · Meyer Children's Hospital IRCCS · starts Dec 4, 2025
- A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)NCT07016802 · Phase 1 · Changchun GeneScience Pharmaceutical Co., Ltd. · starts Jun 9, 2025
- BELux Children OutcoME During A(@)Dulthood With GHDNCT06694506 · Not applicable · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · starts May 21, 2025
- A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.NCT06587035 · Not reported · Pfizer · starts Jan 30, 2025
Trials Authorized in Canada
The 10 newest of 12; search them all in Canada trials| Nov 8, 2022 | A multicenter, open-label, extension trial to investigate long term efficacy and safety of lonapegsomatropin in adults with growth hormone deficiencyLONAPEGSOMATROPIN | Ascendis Pharma | Ongoing |
| Apr 22, 2021 | Foresight: a multicenter, randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial to compare the efficacy and…LONAPEGSOMATROPIN | Ascendis Pharma | Ongoing |
| Apr 18, 2019 | A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily norditropin® in children with short stature…SOMAPACITAN | Novo Nordisk | Closed |
| Mar 5, 2019 | A trial comparing the effect and safety of once weekly dosing of somapacitan with daily norditropin® in children with growth hormone deficiency.NNC0195-0092 (SOMAPACITAN) / NORDITROPIN FLEXPRO | Novo Nordisk | Ongoing |
| Jul 24, 2018 | Enlighten: a multicenter, phase 3, long-term, open-label trial investigating safety and efficacy of transcon hgh administered once-weekly in children with…TRANSCON HGH (ACP-011) | Ascendis Pharma | Pending |
| Aug 24, 2017 | A multicenter, phase 3, open-label, 26-week trial investigating the safety, tolerability and efficacy of transcon hgh administered once weekly in children with…TRANSCON HGH (ACP-011) | Ascendis Pharma | Ongoing |
| Dec 20, 2016 | A multicenter, phase 3, randomized, open-label, active-controlled, parallel-group trial investigating the safety, tolerability, and efficacy of transcon hgh…TRANSCON HGH | Ascendis Pharma | Closed |
| Dec 12, 2016 | A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin therapy in pre-pubertal…MOD-4023 (SOMATROGON) | OPKO BIOLOGICS LTD. | Ongoing |
| Oct 4, 2016 | An open-label, long-term extension study of the safety and efficacy of a long-acting human growth hormone somavaratan (vrs-317) in children with growth hormone…VRS-317 (SOMAVARATAN) | VERSARTIS INC | Closed |
| Dec 2, 2015 | A randomised, multinational, active-controlled, (open-labelled), dose finding, (double-blinded), parallel group trial investigating efficacy and safety of…NNC0195-0092 (SOMAPACITAN) / NORDITROPIN FLEXPRO | Novo Nordisk | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 16| Jul 25, 2025 | Skytrofareplacement of endogenous growth hormone in adults with growth hormone deficiency (GHD) | Ascendis Pharma Endocrinology Division A/S | Approved |
| Jun 27, 2023 | Ngenlatreatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone | Pfizer Ireland Pharmaceuticals | Approved |
| Aug 25, 2021 | SkytrofaTreatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of… | Ascendis Pharma Endocrinology Division A/S | Approved |
| Dec 20, 2017 | MacrelinFor the diagnosis of adult growth hormone deficiency | Aeterna Zentaris GmbH | Approved |
| Dec 15, 1997 | NutropinAs replacement therapy for growth hormone deficiency in adults after epiphyseal closure. | Genentech, Inc. | Approved |
| Oct 31, 1997 | GenotropinTreatment of adults with growth hormone deficiency. | Pharmacia & Upjohn | Approved |
| Sep 26, 1997 | GerefTreatment of idiopathic or organic growth hormone deficiency in children with growth failure. | EMD Serono, Inc. | Approved |
| Oct 8, 1996 | SaizenLong term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone. | EMD Serono, Inc. | Approved |
| Mar 7, 2022 | Growth Hormone Releasing Hormone (GHRH) 1-44 Human Amide…Diagnosis of Growth Hormone Deficiency | Hollenbeck Pharmaceuticals, Inc. | Designated |
| Dec 19, 2019 | recombinant human growth hormone fused to…Treatment of Growth Hormone Deficiency | Alteogen, Inc. | Designated |
| Jun 15, 2017 | ibutamoren mesylateTreatment of growth hormone deficiency | Lumos Pharma LLC | Designated |
| Nov 9, 2016 | recombinant growth hormone fused to hyFcTreatment of growth hormone deficiency. | Genexine, Inc. | Designated |
| Feb 23, 2016 | growth hormone releasing hormone, 1-44 human amideTreatment of growth hormone deficiency | Hollenbeck Pharmaceuticals, Inc. | Designated |
| Oct 16, 2013 | somavaratanTreatment of growth hormone deficiency | Versartis, Inc. | Designated |
| Oct 18, 2012 | pralmorelin hydrochlorideAs a diagnostic agent for the detection of growth hormone deficiency | Sella Pharmaceuticals, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Jan 11, 2022 | Skytrofa (previously Lonapegsomatropin Ascendis Pharma)lonapegsomatropin · orphan | Ascendis Pharma Endocrinology Division A/S | EMA ↗ |
| Mar 31, 2021 | Sogroyasomapacitan | Novo Nordisk A/S | EMA ↗ |
| Jan 11, 2019 | Ghryvelin (previously Macimorelin Aeterna Zentaris)macimorelin | Atnahs Pharma Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA